about
Molecular markers of early Parkinson's disease based on gene expression in bloodLevodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsDevelopmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystoniaDopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit traffickingStriatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystoniaMetabolomics and the search for biomarkers in Parkinson's diseaseImpaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia.Gene expression profiling in the post-mortem human brain--no cause for dismay.Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA.No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain.Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.Effects of gender on nigral gene expression and parkinson disease.Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration.Neuroprotective therapies.Monitoring motor fluctuations in patients with Parkinson's disease using wearable sensors.Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapyEvaluation of AZD1446 as a Therapeutic in DYT1 Dystonia.Racial differences in Parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: a cross-sectional study.Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease.Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodentsAltered dendritic morphology of Purkinje cells in Dyt1 ΔGAG knock-in and purkinje cell-specific Dyt1 conditional knockout mice.Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout miceFiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.Spinal and trigeminal dorsal horn projections to the parabrachial nucleus in the rat.Alteration of striatal dopaminergic neurotransmission in a mouse model of DYT11 myoclonus-dystonia.Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.Expression of the early-onset torsion dystonia gene (DYT1) in human brain.Evaluation of TorsinA as a target for Parkinson disease therapy in mouse modelsAngiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice.Inherited movement disorders.Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's diseaseRationale for and use of NMDA receptor antagonists in Parkinson's disease.Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.A full-brain, bootstrapped analysis of diffusion tensor imaging robustly differentiates Parkinson disease from healthy controlsCD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease.LRRK2 inhibition attenuates microglial inflammatory responses
P50
Q24292810-90A97E37-A4D8-479C-A0B0-D1F13F08828CQ27316872-3BF5D563-0A4F-4791-B477-E9C03835478FQ27321884-45618908-9A2A-4EEF-A2A8-32F44E81E686Q28570291-6B53C458-65C8-4C0E-A2C1-21352D21A5ACQ28648007-D1108BAB-A243-4EE9-8C22-DE06179A8903Q30410511-0AB460F9-31AC-46C6-BD45-C910FA359584Q30547556-70DF1833-B7FC-4C1E-822E-95452875F645Q30996882-583DC1C8-661C-4BBC-A67E-41ACFC113BAFQ31061478-3146DF2B-101E-48C4-918C-3E93C9F9A5AFQ33248020-A5628FC6-5D29-4FC9-BA4C-45399044A949Q33248803-28201442-131E-4FE4-A7C4-4E27C86EF1B4Q33269934-0CCDD2C9-593D-4BB8-AB41-341516129BBFQ33281319-BD62FAEE-7B22-4542-9E4F-E221823F777FQ33292417-A4402F54-4B77-425F-8EAA-8117E2F34B06Q33508801-17AE9339-F975-43CA-9A32-EECD8346CF50Q33545307-9B4980A2-7E9E-41A0-B72E-E05255F1885AQ33689217-37D13865-2AC6-467B-81B6-875C3E278B21Q33700352-B717A322-1415-423B-A9CE-62E2B3406A30Q33790163-FD72C176-7AFF-48DA-A3A0-4BF811A9A2C3Q33802254-E6FA412F-2D85-43B5-BF19-1885278C1C34Q33816700-6DF103A6-B3BA-4957-86C7-F25A82115D56Q33825413-1D52913B-A022-44D2-93BD-2E246CE59060Q33867544-44C4459C-4505-4E6F-AA16-9E31534C2033Q34023627-90A93075-9DEE-4438-A666-8B5347734A17Q34102305-F2859537-9970-4128-8B0D-0771ED23B674Q34192315-4C267FB7-8D2D-4AA0-B9BF-24347BA36FFFQ34206423-C5FEBB50-69B0-45E9-B835-4F6F1F5779E6Q34287439-C4A3AFD4-B86D-476D-8DFC-A3C5BD5E37FDQ34467898-D715F060-B875-4746-A034-8821F8A7E467Q34490978-1539D1FA-4306-46CA-8064-BB3805FA4583Q34586625-09017F26-BC48-4438-814B-5A44A4CB67C7Q34997873-D9E11214-9070-42BB-AD38-B34B5DB1CB5CQ35510197-58C4D004-D2C2-4BFF-B3D6-FF8FB24DFD28Q35603272-5339C795-1C1D-4E10-B7BA-01769BF8A5F6Q35645487-D51C6152-6B11-4B87-BF82-89F0092C50FAQ35784328-236A570B-A1DA-4F7A-A5FE-B4B6E8810D22Q35808359-0BC0BC23-9379-4567-9BE1-CBFB395EBEC2Q35838118-BBD998F1-F5F9-4548-94E1-2A30C218E5E4Q36449229-4BA08D66-20EB-444D-AD2C-314F7C477013Q36493605-11D1F206-482A-48F1-A8D1-DCBBE36FD4C0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David G. Standaert
@ast
David G. Standaert
@en
David G. Standaert
@es
David G. Standaert
@nl
David G. Standaert
@sl
type
label
David G. Standaert
@ast
David G. Standaert
@en
David G. Standaert
@es
David G. Standaert
@nl
David G. Standaert
@sl
altLabel
David G Standaert
@en
David Standaert
@en
prefLabel
David G. Standaert
@ast
David G. Standaert
@en
David G. Standaert
@es
David G. Standaert
@nl
David G. Standaert
@sl
P106
P1153
56926372900
P21
P2798
P31
P4012
P496
0000-0003-2921-8348